Executive Summary
Seven-year TAVR/SAVR durability data are now comparable for structural valve deterioration in severe aortic stenosis, per a JAMA analysis that lands inside the window ESC 2025 cited when it lowered its TAVI age threshold to 70. On the same day, Boston Scientific committed $1.5B to MiRus with an acquisition option — the maker of the nickel-free Siegel valve whose FIH/EFS data at New York Valves 2026 showed 8.5% pacemakers and 2-year mean gradients of 7.8 mm Hg across 35 patients. Both datapoints tighten the ESC's case for expanded TAVI at 70+ and raise the strategic stakes for Edwards' Sapien franchise — though neither answers the durability question below age 65 that ACC/AHA 2020 still guards.
- JAMA 7-year data show comparable TAVR/SAVR valve durability in severe AS, aligning with the evidence base ESC 2025 used to move TAVI to Class I at ≥70 (JAMA).
- Boston Scientific's $1.5B MiRus investment with an acquisition option signals a serious BSX push into TAVI — a market Edwards and Medtronic have owned (Yahoo Finance).
- A Japanese nationwide registry of 12,393 patients found TAVR+PCI outcomes independent of hospital volume, while SAVR+CABG mortality doubled at low-volume centers (adjusted OR 2.07) (Cardiovasc Interv Ther).
- Dialysis TAVR patients had 2.4× higher 5-year mortality (aHR 2.38) driven by non-cardiac infection, not valve failure — reframing the risk conversation for ESRD referrals (Int J Cardiol Heart Vasc).
- Edwards received FDA approval for its Ecliptis system, a structural heart pipeline win landing days before the July 23 earnings print (GuruFocus).
What to watch: Edwards Lifesciences reports Q2 earnings July 23 (consensus $0.74 EPS, $1.70B revenue) — the first read on whether Ecliptis approval and TAVI volume growth offset the durability narrative BSX just bought into.
Aortic Valve (TAVR/TAVI)
The JAMA 7-year TAVR vs. SAVR durability paper shows comparable structural valve deterioration at seven years — extending the durability signal that drove ESC 2025 to designate TAVI Class I at age ≥70. The ACC/AHA 2020 framework — SAVR preferred below 65, shared decision 65–80 — was anchored to data extending only to approximately 5 years; seven years narrows the gap but does not close it. SVD in surgical bioprostheses accelerates after year eight, and matched 10-year TAVR data in low-risk cohorts remain absent. Two additional caveats deserve prominence: TAVR patients in longitudinal comparisons skew older with shorter denominator survival, which biases apparent durability upward; and SVD definitions across trials and registries remain non-uniform, a critique Kaul and Miller have made publicly. The ESC 2025 acknowledged both. [NOTABLE]
A Japanese nationwide registry (n=12,393) reframes the volume-outcome conversation for concomitant AS and CAD: TAVR+PCI mortality was 3.3% versus 5.1% for SAVR+CABG despite older, frailer TAVR patients, and TAVR outcomes were flat across volume quartiles while SAVR+CABG mortality doubled at low-volume centers (aOR 2.07). The data are retrospective and unadjusted for anatomic selection — but they make a real argument for TAVR access in community hospitals while simultaneously arguing for surgical regionalization, not against surgery. ACC/AHA 2020 places patients under 65 with low surgical risk at experienced surgical centers; ESC 2025 raises that threshold to 70, defined as STS-PROM + EuroSCORE II <4%. Neither guideline endorses low-volume SAVR.
A single-center matched cohort (n=278) confirmed dialysis patients face 2.4× higher 5-year mortality after TAVR (aHR 2.38), with >50% of deaths non-cardiac and infection-driven; reintervention and disabling stroke rates were unchanged. Baseline moderate-severe TR independently predicted mortality — a reminder that undertreated TR is a whole-system problem that follows these patients into the TAVI suite. BAV TAVR sex-based mortality at 4.5-year median follow-up (n=327) showed no significant sex difference despite men carrying 2× the calcium burden — reassuring for BAV selection, but BAV TAVR remains Class IIb in both ACC/AHA 2020 and ESC 2025. A TAVR failure review flags the field's persistent skew toward reintervention over prevention, a fair critique as valve-in-valve volumes climb.
Mitral Valve (MitraClip, PASCAL, TMVR)
No mitral-specific studies today. The absence is worth naming against the current guideline backdrop: ESC 2025 elevated TEER for ventricular secondary MR to Class I, LOE A — based on COAPT 5-year follow-up, RESHAPE-HF2, and pooled meta-analysis — one full class above ACC/AHA 2020's IIa. That gap matters for U.S. reimbursement conversations Abbott and Edwards will run through 2026: European TEER volume in SMR now has Class I guideline tailwind; U.S. volume growth still lacks it. Market-tracker coverage of the transcatheter valve replacement space continues to emphasize commercial expansion in mitral and tricuspid with that European tailwind as the primary near-term driver. On primary MR, ESC 2025's Class I recommendation for early repair in asymptomatic patients meeting three of four risk factors (AF, pulmonary hypertension, LA dilation, ≥moderate TR) casts a wider net than ACC/AHA 2020's IIa threshold — a difference that will widen surgical referral volumes at centers following European practice.
Tricuspid Valve (TriClip, TTVR)
Quiet news day for tricuspid, but the field's trajectory runs through a single guideline inflection: ESC 2025 upgraded transcatheter TV treatment for symptomatic severe TR to Class IIa, LOE A — built on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — from zero transcatheter TR recommendations in ACC/AHA 2020. The market analyst coverage singles out TR as the highest-growth structural heart segment, consistent with the STS/ACC TVT Registry EVOQUE experience (98.4% technical success, 3.1% 30-day mortality) that anchors the reference base. The surgical benchmark these transcatheter outcomes must beat — historical isolated TV surgery mortality of 8–20% — reflects the too-late-referral problem both guidelines flag; contemporary series with earlier referral show substantially improved results, and ESC 2025 upgraded symptomatic primary TR to a Class I surgical indication precisely to force earlier action. The dialysis TAVR paper's finding that baseline moderate-severe TR independently predicted mortality underscores the point: undertreated TR compounds risk across every structural heart intervention, not just in the tricuspid clinic.
Device & Technology
The MiRus Siegel valve FIH/EFS results at New York Valves 2026: 35 patients, one non-valve-related death by 6 months, three pacemakers (8.5%), no strokes, no annular rupture, no moderate/severe AR. The 2-year mean gradient of 7.8 mm Hg and 23-mm valve gradient of 8.3 mm Hg at 6 months stand out against the double-digit gradients common with small commercial valves. Rhenium frame, nitric oxide coating, dry porcine leaflets, 8-Fr expandable sheath, no foreshortening. Circularity ratios (1.02 tricuspid, 1.03 bicuspid) beat published Sapien and Evolut values.
The honest context: N=35, single presenter's data, no comparator arm, three patients with severe nickel allergy who had no other option — a highly selected early cohort. The STAR trial now randomizing 1,000 patients against a commercial control is the test that matters. BSX evidently found the early data credible enough to commit $1.5B. Separately, Edwards received FDA approval for the Ecliptis system, a pipeline win landing three weeks before earnings.
Regulatory & Policy
FDA approval of Edwards' Ecliptis system is the regulatory event, though public detail on indication and label is limited today (GuruFocus). A newly posted Chinese trial (NCT07677410) plans 1,172 patients randomized to aspirin monotherapy vs. sequential warfarin-then-aspirin post-TAVR for pure aortic regurgitation — a population ESC 2025 covers with a Class IIb TAVI recommendation for inoperable AR and where antithrombotic strategy has no RCT base.
Industry & Market
Boston Scientific's $1.5B MiRus deal — equity stake plus TAVR acquisition option — is the industry story of the quarter. BSX has been the notable absence in the TAVI duopoly. This is their entry point, timed to the Siegel EFS readout. RBC's coverage note argued Edwards can sustain strong revenue growth on technological leadership, but that thesis now faces a credible third entrant. Ecliptis approval is Edwards' near-term counter-move.
Financial Analysis
The BSX-MiRus deal reprices the competitive risk premium on Edwards' TAVI franchise. Edwards trades at 48.9 trailing P/E — a premium built on TAVI durability leadership and pipeline optionality. If the Siegel valve replicates its EFS hemodynamics in the STAR pivotal, that premium compresses. Ecliptis approval and continued TAVI volume growth support it in the near term. Q2 earnings July 23 is the first read (consensus $0.74 EPS, $1.70B revenue). BSX is down 55% over six months, distorted by broader medtech re-rating — the MiRus commitment is a capital allocation signal that management believes TAVI is where structural heart operating leverage still lives. Multiple Edwards insider 10b5-1 sales hit the tape today — routine calendar sales, not a directional signal.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $90.46, down 0.79% on the day; 6-month return +6.01%.
- Market cap $52.1B; trailing P/E 48.9, forward P/E 26.9; beta 0.87; 52-week range $72.30–$92.88.
- Analyst consensus $96.92 (26 analysts, range $84–$110); buy.
- Q2 earnings July 23: EPS est $0.74, revenue est $1.70B.
- Ecliptis FDA approval and continued TAVI momentum offset near-term competitive noise from BSX-MiRus; premium multiple assumes durability leadership holds.
Medtronic (MDT)
- Close $78.23, down 3.34%; 6-month return -17.15%.
- Market cap $100.1B; trailing P/E 21.0, forward P/E 12.2; beta 0.60.
- Analyst consensus $97.77 (range $78–$121); buy.
- Next earnings Aug 18: EPS est $1.39, revenue est $9.55B.
- Evolut franchise faces the same durability-narrative pressure as Sapien, with less near-term pipeline catalyst than Edwards.
Abbott (ABT)
- Close $90.74, down 2.12%; 6-month return -26.10%.
- Market cap $158.1B; trailing P/E 25.4, forward P/E 15.0; beta 0.62.
- Analyst consensus $116.54; buy.
- Q2 earnings July 16: EPS est $1.28, revenue est $12.52B.
- MitraClip and TriClip franchises stand to benefit from ESC 2025 Class I TEER-for-SMR in European volume; U.S. practice change lags guideline change.
Boston Scientific (BSX)
- Close $42.68, down 1.84%; 6-month return -54.94%.
- Market cap $63.4B; trailing P/E 17.9, forward P/E 11.5; beta 0.56.
- Analyst consensus $75.00 (range $55–$106); buy.
- Q2 earnings July 29: EPS est $0.83, revenue est $5.37B.
- $1.5B MiRus investment is the structural heart headline; STAR trial readout is the multi-year swing factor.
Anteris Technologies (AVR.AX)
- Close A$13.70, essentially flat; 6-month return +83.96%.
- Market cap A$1.3B; forward P/E negative (pre-revenue commercial stage).
- Sole analyst target A$13.00.
- DurAVR THV pivotal progression remains the key catalyst; small float, high volatility.
Outlook: BSX's MiRus commitment converts TAVI from a two-horse race into a contested market. Near-term, that supports Edwards' Ecliptis-driven optionality and pressures Medtronic. The JAMA durability data and the ESC 2025 age threshold shift together enlarge the addressable market for all TAVI manufacturers while reopening the durability critique surgical societies have consistently pressed. Note that Meril, JenaValve, and J Valve remain private.
Clinical Trial Updates
Aortic
- NCT07677410: Aspirin Monotherapy vs Sequential Warfarin-Aspirin After TAVR in Pure AR — status Not Yet Recruiting; enrollment 1,172; sponsor Shanghai Zhongshan Hospital; last updated 2026-06-30. Fills an antithrombotic evidence gap in the pure-AR TAVI population, which sits at ESC 2025 Class IIb.
- STAR trial (referenced at New York Valves 2026): 1,000-patient randomization of MiRus Siegel vs commercial TAVI valves — the read that will determine whether BSX's $1.5B call proves out.
Mitral Repair / Replacement: No status changes today. Watch REPAIR-MR (early primary MR repair vs surveillance), which speaks directly to the ACC/AHA IIa vs ESC 2025 Class I disagreement on asymptomatic patients.
Tricuspid Repair / Replacement: No status changes today. TRISCEND II and TRILUMINATE long-term follow-up remain the ESC 2025 Class IIa foundation.
What's Next
Edwards Q2 earnings on July 23 will show whether Ecliptis approval and TAVI unit growth outrun the competitive re-rating BSX's MiRus deal just triggered — and whether the JAMA 7-year durability signal is being priced as tailwind or as a delayed reckoning.